Proposed framing. Nothing on this page is an investment offer or a live raise.
The funding gap
CHR-P programmes ask long, careful questions. Endpoints can be slow and enrichment-sensitive. That profile often sits poorly with funds that need short, binary “win” narratives. The result: good science can stall for lack of catalytic capital, not lack of importance.
What a DeSci-aligned approach could add
- Access to newer capital constituencies (including crypto-native family offices and mission-aligned DeSci investors) alongside specialist life-sciences capital
- Transparent, programme-specific use of proceeds
- We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
- Never a DEX or retail mint as the funding path
Accountability boundaries
- NWPharmaTech remains pharmaceutical sponsor — clinical decisions are not token-voted
- No parent-company equity sale under this mandate
- Families and patients are never routed into capital funnels
- This website remains educational; it does not accept investment
Meaningful participation without a wallet
Today: follow updates, send research or press enquiries, read the science library, critique our communications. Tomorrow (if financing proceeds): only legally eligible counterparties via a private process — separate from supporter registration.